Guangzhou Huayue Renal Regenerative Medicine Technology

Guangzhou Huayue Renal Regenerative Medicine Technology is a pioneering biotechnology company focused on solving the global shortage of transplantable organs through renal regeneration. The company leverages advanced induced pluripotent stem cell (iPSC) technology and CRISPR-based gene editing to develop humanized kidneys within chimeric pig embryos. By integrating developmental biology with xenotransplantation techniques, Huayue aims to create functional, patient-specific organs for the treatment of end-stage renal disease. Their research represents a significant milestone in regenerative medicine, specifically in the field of interspecies organogenesis. The company operates as a commercial translation vehicle for breakthroughs achieved at the Guangzhou Institutes of Biomedicine and Health.